Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2007-06-12
2007-06-12
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
Reexamination Certificate
active
10258222
ABSTRACT:
The present invention is directed to a method of modulating the release of at least one endogenous compound in vivo. The method comprises delivering intranasally at least one micro-construct comprising an agonist and a pharmaceutically acceptable carrier to a locus comprising an agonist receptor and a heterologous receptor that is coupled to at least one common signaling molecule. The micro-construct used in the present inventive method provides sustained release of the agonist provided by erosion of an exterior surface defined by the micro-construct. Once released, the agonist effectively up- or down-regulates at least one signaling molecule common to both the agonist receptor and the heterologous receptor, thereby potentiating or desensitizing the heterologous receptor in order to modulate release of at least one endogenous compound under the control of the heterologous receptor.
REFERENCES:
patent: 3941127 (1976-03-01), Froning
patent: 4849228 (1989-07-01), Yamamoto et al.
patent: 5171812 (1992-12-01), Domb
patent: 5360610 (1994-11-01), Tice et al.
patent: 5487739 (1996-01-01), Aebischer et al.
patent: 5652220 (1997-07-01), Heya et al.
patent: 5900247 (1999-05-01), Rault et al.
patent: 6180603 (2001-01-01), Frey
patent: 6303134 (2001-10-01), Kubek
patent: 6313093 (2001-11-01), Frey
patent: 6491939 (2002-12-01), Kubek
patent: 0256726 (1988-02-01), None
patent: 0781550 (1999-05-01), None
patent: WO 98/08464 (1998-03-01), None
Born et al., “Sniffing Neuropeptides: A Transnasal Approach to the Human Brain,”Nature Neuroscience, vol. 5, No. 6, 514-516 (2002).
Chepurnov et al., “Neuropeptide Thyroliberin—Adaptive Endogenous Anticonvulsant Defense of Brain.”
Chepournova et al., “P8/21 Thyrotropin Releasing Hormone (TRH) in Ultra Low Doses Decreases Severity of Seizures in Rats,”Neuropeptides26 (Supp. 1):52 (1994) (Abstract).
Domb et al., “Drug Delivery to the Brain Using Polymers,”Critical Reviews In Therapeutic Drug Carrier Systems, 8(1):1-17 (1991).
Green et al., “GiDown-regulation as a Mechanism for Heterologous Desensitization in Adipocytes,”The Journal Of Biological Chemistry, vol. 267, No. 5, pp. 3223-3229 (1992).
Grossman et al., “The Intracerebral Distribution of BCNU Delivered by Surgically Implanted Biodegradable Polymers”,J Neurosurg76:640-647 (1992).
Kim et al., “The Long Isoform of Rat Throtropin-releasing Hormone Receptor Down-regulates GqProteins,”Journal Biology Chemistry, vol. 269(31), pp. 19933-19940 (1994).
Kokaia et al., “Seizure suppression in kindling epilepsy by intracerebral implants of GABA—but not by noradrenaline-releasing polymer matrices,”E P Brain Res100:385-394 (1994).
Kubek, et al., “Issues Related to Intranasal Delivery of Neuropeptides to Temporal Lobe Targets,” Published in:Proceedings of the 44thOholo Conference on: The Blood Brain Barrier, Drug Delivery and Brain Pathology, D. Kobiler, S. Lustig, S. Shapir, Eds., Kluwer Academic/Plenum, New York, 323-350 (2001).
Mason et al., “Thyrotropin-releasing Hormone,”The American College of Neuropsychopharamacology, http://www.acnp.org/G4/GN401000048/CH048.html, pp. 1-11 (2000).
Milligan, “Agonist regulation of cellular G protein levels and distribution: mechanisms and functional implications,”TIPS, vol. 14, pp. 413-418, (Nov. 1993).
Mori et al., “Anticonvulsant Effect of DN-1417, a Derivative of Thyrotropin-Releasing Hormone, and Liposome-Entrapped DN-1417, on Amygdaloid-Kindled Rats,”Epilepsia, 33(6):994-1000 (1992).
Ron et al., “Controlled release of polypeptides form polyanhydrides,”Proc. Nat'l. Acad. Sci. USA, vol. 90, 4176-4180 (1993).
Saunier et al., “Cyclic AMP Regulation of Gs Protein,”The Journal of Biological Chemistry, vol. 265, No. 32, 19942-19946 (1990).
Strader et al., “The Family of G-protein-coupled Receptors,”The FASEB Journal, vol. 9, 745-754 (Jun. 1995).
Tamargo et al., “Interstitial Chemotherapy of the 9L Gliosarcoma: Controlled Release Polymers for Drug Delivery in the Brain,”Cancer Res.53:329-33 (1993).
Svoboda et al., “Thyrotropin-Releasing Hormone-Induced Subcellular Redistribution and Down-regulation of G11α: Analysis of Agonist Regulation of Coexpressed G11αSpecies Variants,”Molecular Pharmacology, 49:646-655 (1996).
Azpuru Carlos A.
Indiana University Research and Technology Corporation
Leydig , Voit & Mayer, Ltd.
LandOfFree
Pharmacotherapeutic process and composition for central... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmacotherapeutic process and composition for central..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacotherapeutic process and composition for central... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3878203